These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 23564760)

  • 1. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
    Al-Ejeh F; Shi W; Miranda M; Simpson PT; Vargas AC; Song S; Wiegmans AP; Swarbrick A; Welm AL; Brown MP; Chenevix-Trench G; Lakhani SR; Khanna KK
    J Nucl Med; 2013 Jun; 54(6):913-21. PubMed ID: 23564760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
    von Minckwitz G; Müller BM; Loibl S; Budczies J; Hanusch C; Darb-Esfahani S; Hilfrich J; Weiss E; Huober J; Blohmer JU; du Bois A; Zahm DM; Khandan F; Hoffmann G; Gerber B; Eidtmann H; Fend F; Dietel M; Mehta K; Denkert C
    J Clin Oncol; 2011 Jun; 29(16):2150-7. PubMed ID: 21519019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
    Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
    Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
    BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
    Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
    Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
    Yagata H; Kajiura Y; Yamauchi H
    Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panitumumab-DOTA-
    Facca VJ; Cai Z; Gopal NEK; Reilly RM
    Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.
    Ng B; Kramer E; Liebes L; Wasserheit C; Hochster H; Blank E; Ceriani R; Furmanski P
    Cancer Res; 2001 Apr; 61(7):2996-3001. PubMed ID: 11306478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance.
    Nevo J; Mattila E; Pellinen T; Yamamoto DL; Sara H; Iljin K; Kallioniemi O; Bono P; Heikkilä P; Joensuu H; Wärri A; Ivaska J
    Clin Cancer Res; 2009 Nov; 15(21):6570-81. PubMed ID: 19825952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer].
    Hashimoto K; Tamura K
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1187-91. PubMed ID: 20647696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The paradox of triple negative breast cancer: novel approaches to treatment.
    Fornier M; Fumoleau P
    Breast J; 2012; 18(1):41-51. PubMed ID: 22098334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.
    Luo TY; Tang IC; Wu YL; Hsu KL; Liu SW; Kung HC; Lai PS; Lin WJ
    Nucl Med Biol; 2009 Jan; 36(1):81-8. PubMed ID: 19181272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
    Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
    Mol Pharm; 2015 Nov; 12(11):3963-72. PubMed ID: 26402157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.